\begin{table}[!h]
\centering
\caption{\label{tab:tab:study_characteristics_by_molecule}Résumé agrégé par molécule (comptage par \emph{étude}): nombre d’études et de participants, disponibilité des fenêtres, plages et nombre de doses actives par fenêtre, et répartition des types de placebo (présence par étude).}
\centering
\begin{tabular}[t]{lrrrr>{\raggedleft\arraybackslash}p{2.4cm}r>{\raggedleft\arraybackslash}p{2.7cm}r>{\raggedleft\arraybackslash}p{2.0cm}>{\raggedleft\arraybackslash}p{2.0cm}>{\raggedleft\arraybackslash}p{2.0cm}>{\raggedleft\arraybackslash}p{2.0cm}r}
\toprule
Molecule & Studies & Participants (study-level sum) & Studies with Session & Studies with Follow-up & Dose range (Session, mg) & \# active doses (Session) & Dose range (Follow-up, mg) & \# active doses (Follow-up) & Studies w/ Inactive placebo & Studies w/ Active non-psy placebo & Studies w/ Active psychedelic comparator & Studies w/ Placebo unspecified & Unique AE terms (sum)\\
\midrule
\cellcolor{gray!10}{AYAHUASCA} & \cellcolor{gray!10}{2} & \cellcolor{gray!10}{46} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{—} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{—} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{2} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{16}\\
LSD & 6 & 305 & 0 & 3 & — & 0 & 0.1–200 & 6 & 2 & 0 & 2 & 0 & 84\\
\cellcolor{gray!10}{MDMA} & \cellcolor{gray!10}{10} & \cellcolor{gray!10}{403} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{3} & \cellcolor{gray!10}{—} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{75.0–125} & \cellcolor{gray!10}{2} & \cellcolor{gray!10}{7} & \cellcolor{gray!10}{1} & \cellcolor{gray!10}{2} & \cellcolor{gray!10}{0} & \cellcolor{gray!10}{164}\\
PSILOCYBIN & 8 & 517 & 0 & 0 & — & 0 & — & 0 & 4 & 3 & 1 & 0 & 134\\
\bottomrule
\end{tabular}
\end{table}
